References in periodicals archive ?
"KPTI's port training program is excellent, and the facilities and faculty are world class," remarked Privratsky during an interview with local media.
(Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases.
Karyopharm (KPTI), up 2% after announcing three presentations highlighting new and updated data from the Phase 1b/2 STOMP study evaluating selinexor...
Quiet a few approvals came through, including Eli Lilly And Co (NYSE:LLY)'s nasally administered low blood sugar drug, Karyopharm Therapeutics Inc (NASDAQ: KPTI)'s Selinexor and a handful of generic drugs.
Karyopharm Therapeutics (KPTI) up 3.4% after Point72 disclosed passive stake...
Jefferies analyst Maury Raycroft highlights Karyopharm Therapeutics (KPTI) and Reata Pharmaceuticals (RETA) as two stocks to focus on in 2019.
Karyopharm (KPTI) downgraded to Neutral from Outperform at Wedbush with analyst David Nierengarten citing valuation.
Karyopharm (KPTI), down 3% after the stock was downgraded to Neutral from Outperform at Wedbush...
MAJOR MOVERS: Among the noteworthy gainers was Karyopharm (KPTI), which rose 11% after it reported "positive" top-line results from the Phase 2b STORM study.
MAJOR MOVERS: Among the noteworthy gainers was Karyopharm (KPTI), which rose 15% after it reported "positive" top-line results from the Phase 2b STORM study.
HIGHER: Karyopharm (KPTI) up 22% after reporting top line data from a Phase 2b Selinexor study that JPMorgan analyst Eric Joseph said "look very solid"...
ALSO HIGHER: Karyopharm (KPTI) up 26.2% after positive top line data from Phase 2b Selinexor study...
Acronyms browser ?
Full browser ?